Yükleniyor... / Loading...
This study evaluates the glutaminase inhibitor CB-839, alone and in combination with other drugs, in patients with advanced solid tumors. Adults with relapsed or treatment-refractory advanced cancer, good general condition (ECOG 0-1), and measurable disease were able to take part. The study was carried out in Phase 1 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion criteria * Advanced malignancy that is relapsed and/or refractory to all available therapies that will confer clinical benefit. Newly diagnosed patients who refuse standard treatment regimens are also eligible * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 * Life Expectancy of at least 3 months * Adequate hepatic, renal, cardiac, and hematologic function * Measurable disease by RECIST criteria * Ability to provide written informed consent in accordance with federal, local, and institutional guidelines Exclusion Criteria * Any other current or previous malignancy * Chemotherapy, radiation therapy, hormonal therapy, immunotherapy or biological therapy, or investigational agent within 21 days * Unable to receive medications oral medications * Major surgery within 28 days before Cycle 1 Day 1 * Active infection requiring within 2 weeks prior to first dose of study drug * Patients who have HIV, Hepatitis A, B or C or CMV reactivation * Significant neurotoxicity/neuropathy (Grade 3 or higher) within 14 days of first dose of study drug * Conditions that could interfere with treatment or protocol-related procedures